Related Experiment Video
Updated: Dec 21, 2025
Optimization of a Quantitative Micro-neutralization Assay
Published on: December 14, 2016
Characterization of neutralizing monoclonal antibody against tick-borne encephalitis virus in vivo
Andrey Matveev1, Leonid Matveev1, Oleg Stronin2
1Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia.
Abstract:
Tick-borne encephalitis virus (TBEV) is the most important tick-transmitted pathogen in the family Flaviviridae and causes one of the most severe human neuroinfections. In this study, a neutralizing mouse mAb 14D5, which was previously shown to have cross-reactive binding to several flaviviruses belonging to the TBEV group, was examined for its prophylactic and therapeutic effects in BALB/c mice infected with TBEV. Before and after infection, mice were administrated mAb 14D5 at doses 100 μg and 10 μg per mouse. mAb 14D5 showed clear protective efficacy when injected at the high dose one day after infection, with survival rates that were TBEV dose-dependent. Prophylactic administration of mAb 14D5 was more effective than post-exposure administration and complete protection was documented when the mAb was administered one day before infection. The protective efficacy of mAb 14D5 was significantly higher than that of the anti-TBE serum immunoglobulin. However, no protection was observed in mice received the low dose of mAb 14D5 independent of the timing of mAb injection and TBEV dose. The ability of species-matched mAb 14D5 to mediate TBEV infection in mice was also investigated, and the results indicated that mAb 14D5 did not augment TBEV infection independent of the time of mAb administration. The neutralizing epitope for mAb 14D5 was localized in domain III of glycoprotein E of TBEV in a region between residues 301-339, which is conserved among flaviviruses from the TBEV group.
Insights
A neutralizing mouse antibody (mAb 14D5) demonstrated significant protective effects against tick-borne encephalitis virus (TBEV) infection in mice, especially when administered prophylactically. High doses were effective, while low doses showed no protection.
Area of Science:
- Virology
- Immunology
- Neuroscience
Background:
- Tick-borne encephalitis virus (TBEV) is a significant flavivirus causing severe human neuroinfections.
- Neutralizing monoclonal antibodies (mAbs) are crucial for understanding and combating viral infections.
- Previous studies identified mAb 14D5 with cross-reactive binding to TBEV group flaviviruses.
Purpose of the Study:
- To evaluate the prophylactic and therapeutic potential of mouse mAb 14D5 against TBEV infection.
- To determine the dose-dependency and optimal timing for mAb 14D5 administration.
- To compare the efficacy of mAb 14D5 with anti-TBE serum immunoglobulin.
Main Methods:
- BALB/c mice were infected with TBEV and treated with varying doses (100 μg and 10 μg) of mAb 14D5.
- Administration timing included prophylactic (pre-infection) and therapeutic (post-infection) approaches.
- Survival rates were assessed, and the potential for antibody-dependent enhancement of infection was investigated.
Main Results:
- High-dose (100 μg) mAb 14D5 administration showed clear protective efficacy, particularly when given prophylactically.
- Complete protection was achieved when mAb 14D5 was administered one day before TBEV infection.
- Low-dose (10 μg) mAb 14D5 provided no protection, and its efficacy was superior to anti-TBE serum immunoglobulin.
Conclusions:
- Mouse mAb 14D5 exhibits significant prophylactic and therapeutic potential against TBEV infection in a dose-dependent manner.
- Prophylactic administration of high-dose mAb 14D5 is more effective than post-exposure treatment.
- The neutralizing epitope of mAb 14D5 is located in domain III of TBEV glycoprotein E (residues 301-339).
